BlackRock’s Citius Oncology CTOR Stock Holding History

BlackRock’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.4K	Buy	47,454 +25,110	+112%	+$25.2K	﹤0.01%	5239
2025 Q4	$22.3K	Buy	+22,344	New	+$32.1K	﹤0.01%	5199

Other funds holding CTOR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

BlackRock's CTOR Position: Q1 2026 in Review

BlackRock increased its Citius Oncology (CTOR) stake by 112% in Q1 2026, buying an estimated $25.2K and bringing the position to 47,454 shares worth $29.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5239.

BlackRock first reported a position in CTOR in Q4 2025 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

BlackRock held 47,454 shares of Citius Oncology worth $29.4K as of Q1 2026.
BlackRock bought 25,110 Citius Oncology shares in Q1 2026, an estimated $25.2K.
Citius Oncology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5239 holding.
BlackRock first reported a position in Citius Oncology in Q4 2025 and has held it in 2 quarters since.
14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.